{"id":128251,"date":"2022-03-14T10:01:20","date_gmt":"2022-03-14T14:01:20","guid":{"rendered":"https:\/\/44.250.171.167\/?p=128251"},"modified":"2022-10-05T06:22:35","modified_gmt":"2022-10-05T10:22:35","slug":"solara-active-pharma-sciences-limited-q3-fy22-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/solara-active-pharma-sciences-limited-q3-fy22-earnings-conference-call-insights\/","title":{"rendered":"Solara Active Pharma Sciences Limited Q3 FY22 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Solara Active Pharma Sciences Limited Q3 FY22 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/mZLf2s4bnQ8?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Solara Active Pharma Sciences Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/SOLARA\/\">SOLARA<\/a>) Q3 FY22 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Kunal Randeria from Edelweiss asked about the strategic change that the company had done that has led to a decline. Bharath Sesha MD CEO stated that it was more related to the stocks that it has than business with its channel partners. Since the demand was less, channel partners also [stocked] the inventory which led to a consequent pricing issue. So SOLARA took back the sales from the channel partners. SOLARA added that this is not affecting the regulated markets or the regulated customers.<\/li>\n<\/ul>\n<ul>\n<li>Mitesh Shah from ICICI Securities asked about the revenue expectation in 4Q22 and FY23. Raj MD said that had the one-timer not been there, the company would have been around INR400 crores plus. The visibility of order book is at much higher level what it used to have in last 2-3 quarters. SOLARA is now seeing things on the Ibu front getting revived and getting back to normal level of Ibu sales. CRAMS business is also doing well.<\/li>\n<\/ul>\n<ul>\n<li>Mitesh Shah from ICICI Securities also asked about margins in 4Q22 and pricing in Ibuprofen. \u00a0Raj MD said it\u2019s ibuprofen margins that have come down due to demand stress and stocks in the market. Secondly slight rise in two critical KSMs. SOLARA has to see the price stabilization in the Ibu raw materials and hope to see some amount of consistency coming in 4Q22. In terms of demand stabilization, the company expects some stabilization happening in 4Q.<\/li>\n<\/ul>\n<ul>\n<li>Nitin Agarwal from DAM Capital asked about business in terms of topline perspective next year. Subhash Anand CFO replied that the company is already at INR400-450 crore as a normalized revenue for FY22. The new products are coming and adding to the next year base which are in ramp up phase and that\u2019s going give a ramp up to the company. Aurore merger will also add to the ram up of growth.<\/li>\n<\/ul>\n<ul>\n<li>Nitin Agarwal from DAM Capital also asked about the gross margin range for SOLARA. Subhash Anand CFO replied that the company will continue to have a gross margin range of around 50-54% range. And the company is confident that once the raw material volatility settles, which is expected to happen soon, SOLARA will be back in the normal range of GM.<\/li>\n<\/ul>\n<ul>\n<li>Nitin Agarwal from DAM Capital asked about the backward integration of Ibu coming through and the status of that. Raj MD answered that the company is doing some trial batches in 4Q22 with the new facility, but expect to commercialize in 1Q23.<\/li>\n<\/ul>\n<ul>\n<li>Aejas Lakhani from Unifi Capital asked about the quantum of inventory that was called back in the quarter. Subhash Anand CFO replied that the company had an expected sales return of around INR120-130 crore.<\/li>\n<\/ul>\n<ul>\n<li>Bhaskar Bukrediwala from Arthya Investments asked that in Ibu even if demand had to revive, what\u2019s the thought on supply and the impact on utilization. Raj MD replied that the company\u2019s backward integration strategy with IBB and IBAP will help to sustain the competition and will also expand the derivative sales.<\/li>\n<\/ul>\n<ul>\n<li>Manish Gupta from Solidarity Advisors asked that on the Aurore merger what\u2019s the quantum of cost synergies that the company has seen. Raj MD replied that at least on a yearly perspective basis INR50 crores.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Solara Active Pharma Sciences Limited (SOLARA) Q3 FY22 Earnings Concall Q&amp;A Highlights: Kunal Randeria from Edelweiss asked about the strategic change that the company had done that has led to a decline. Bharath Sesha MD CEO stated that it was more related to the stocks that it has than business with its [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-128251","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172176,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":128251,"position":0},"title":"Solara Active Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 6, 2025","format":false,"excerpt":"Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. \u00a0 Q2 FY26 Earnings Results: Revenue from Operations: \u20b9314 crore, down 9.6% YoY and 1.9% QoQ from \u20b9320 crore in Q1 FY26. Net Loss: \u20b910.1 crore, reversing from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Solara Active Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169341,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-sciences-ltd-q1fy26-12-fall-in-revenue\/","url_meta":{"origin":128251,"position":1},"title":"Solara Active Pharma Sciences Ltd Q1FY26; 12% fall in Revenue","author":"Chirag Gupta","date":"July 25, 2025","format":false,"excerpt":"Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. Financial Results: Solara Active Pharma Sciences Ltd reported Revenues for Q1FY26 of \u20b9319.00 Crores down from \u20b9363.00 Crore year on year, a fall of 12.12%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":157279,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-sciences-ltd-q2fy24-26-rise-in-revenue\/","url_meta":{"origin":128251,"position":2},"title":"Solara Active Pharma Sciences Ltd Q2FY24; 26% rise in Revenue","author":"Chirag Gupta","date":"December 12, 2023","format":false,"excerpt":"Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. Financial Results: Solara Active Pharma Sciences Ltd reported Revenues for Q2FY24 of \u20b9425.00 Crores up from \u20b9338.00 Crore year on year, a rise of 25.74%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":145960,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-q4fy23-results-out-revenue-grows-by-6\/","url_meta":{"origin":128251,"position":3},"title":"Solara Active Pharma Q4FY23 results out, revenue grows by 6%","author":"Chirag Gupta","date":"May 12, 2023","format":false,"excerpt":"Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139291,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-sciences-limited-solara-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":128251,"position":4},"title":"Solara Active Pharma Sciences Limited (SOLARA) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"January 26, 2023","format":false,"excerpt":"Solara Active Pharma Sciences Limited (NSE:SOLARA) Q3 FY23 Earnings Concall dated Jan. 25, 2023. Corporate Participants: Abhishek Singhal\u00a0--\u00a0Investor Relations Consultant Jitesh Devendra\u00a0--\u00a0Managing Director S. Hariharan\u00a0--\u00a0Executive Director and Chief Financial Officer Analysts: Unidentified Participant\u00a0--\u00a0-- Analyst Mahek Talati\u00a0--\u00a0YellowJersey Investment Advisors -- Analyst Tushar Manudhane\u00a0--\u00a0Motilal Oswal Financial Service Ltd. -- Analyst Nitin Agarwal\u00a0--\u00a0DAM\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":176901,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-sciences-limited-solara-q3-2025-earnings-call-transcript\/","url_meta":{"origin":128251,"position":5},"title":"Solara Active Pharma Sciences Limited (SOLARA) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Solara Active Pharma Sciences Limited (NSE: SOLARA) Q3 2025 Earnings Call dated Jan. 24, 2025 Corporate Participants: Abhishek Singhal \u2014 Investor Relations Arun Kumar \u2014 Founder & Non-Executive Director Poorvank Purohith \u2014 Managing Director & Chief Executive Officer Arun Kumar Baskaran \u2014 Chief Financial Officer Analysts: Amresh Kumar \u2014 Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=128251"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128251\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=128251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=128251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=128251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}